Comparison of risk of individual TNFi therapies with sDMARD therapy
| ETA | INF | ADA | |
|---|---|---|---|
| N=4073 | N=3457 | N=4327 | |
| Follow-up time (patient-years) | 22 146 | 12 379 | 18 027 |
| Follow-up per subject in years: median (IQR) | 4.8 (2.5, 5.0) | 3.9 (1.3, 5.0) | 3.5 (2.0, 4.8) |
| Solid cancers | 190 | 98 | 139 |
| Incidence rate per 10 000 patient-years (95% CI) | 86 (74 to 99) | 79 (64 to 96) | 77 (65 to 91) |
| Unadjusted HR (95% CI)* | 0.74 (0.59 to 0.92) | 0.68 (0.53 to 0.88) | 0.67 (0.53 to 0.84) |
| Age and sex adjusted HR (95% CI) | 1.00 (0.80 to 1.25) | 0.87 (0.67 to 1.12) | 0.84 (0.66 to 1.07) |
| PD-adjusted HR (95% CI) | 0.89 (0.67 to 1.19) | 0.81 (0.59 to 1.11) | 0.79 (0.59 to 1.05) |
*sDMARD was referent for regression analyses.
ADA, adalimumab; ETA, etanercept; INF, infliximab; PD, propensity score stratified into deciles; sDMARD, synthetic disease modifying antirheumatic drug; TNFi, tumour necrosis factor inhibitors.